Exxua
Generic name: gepirone
Treatment for: Major Depressive Disorder
Fabre-Kramer Submits NDA Amendment for Exxua™ for Treatment of Major Depressive Disorder
HOUSTON, Jan. 4, 2023 /PRNewswire/ — Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug Administration (FDA) for its novel mechanism antidepressant Exxua™ (gepirone ER) for treatment of Major Depressive Disorder (MDD).
FDA has previously confirmed Exxua’s efficacy in the treatment of MDD and stated that no relevant safety issues preclude an approval recommendation.
Studied in over 5,000 patients, Exxua’s unique mechanism of targeted single serotonin (5HT) 1a receptor agonism relieves depressive symptoms without significant side effects. Exxua does not cause sexual dysfunction in depressed patients, a common side effect among most available antidepressants. In late 2021 FDA imposed safety labeling warning of serious risk of sexual dysfunction on all SSRI and SNRI products. Exxua was shown superior in sexual functioning to SSRIs in several studies and to not cause any meaningful weight gain.
Fabre-Kramer CEO Stephen Kramer, M.D. said “The submission of this Amendment is the culmination of years of dedicated effort by our team and we look forward to working with FDA on its review. Exxua, once approved, will be the first targeted single serotonin receptor antidepressant, a truly new class, with the potential to benefit millions of MDD patients. There is value in providing prescribers and patients with a wide range of effective options for use in clinical practice.”
Anita H. Clayton, MD, Chair, Department of Psychiatry & Neurobehavioral Sciences, University of Virginia School of Medicine, a renowned clinician and researcher of sexual dysfunction issues in MDD treatment commented “Prevalence of Sexual Dysfunction is a major issue in treatment of MDD. A treatment option (especially working through serotonin systems) for MDD patients who cannot tolerate or don’t want to risk experiencing sexual side effects of available treatments has been needed for a long time.”
Stephen A. Stahl, MD, PhD., Professor of Psychiatry, University of California, founder of the Neuroscience Education Institute and a preeminent psychopharmacologist said “Exxua is the first truly selective agonist of the serotonin 1A receptor that mediates mood and has been consistently linked to mood disorders and suicide risk in human PET (positron emission tomography) studies. By targeting the 1A receptor more selectively than either the SSRI/SNRIs or buspirone, Exxua avoids negative side effects including sexual dysfunction and weight gain.”
About Depression
Major depressive disorder (MDD) is a debilitating, chronic, biologically-based disorder characterized by low mood, inability to feel pleasure, feelings of worthlessness, low energy, and other emotional and physical symptoms, and impairment of important functioning. In severe cases, MDD can result in suicide. According to the US Department of Health and Human Services, an estimated 21 million US adults experience MDD each year. Nearly two-thirds of diagnosed and treated patients do not experience adequate treatment response with available first-line treatment, highlighting the need for additional therapies with new mechanisms of action.
About Exxua
Exxua is a novel oral serotonin (5HT) 1A receptor agonist being developed for the treatment of MDD and other psychiatric disorders.
About Fabre-Kramer
Fabre-Kramer is committed to developing and bringing to market advanced new medications to help physicians treat their patients’ unmet medical needs in the therapeutic areas of psychiatry and neurology. The Company focuses on compounds to license-in, develop for global registration, and license-out to commercial partners. The Company looks forward to discussions with potential partners to bring Exxua to market once approved.
Source: Fabre-Kramer
Posted: January 2023
Related articles
- FDA Approves Exxua (gepirone) for the Treatment of Major Depressive Disorder in Adults - September 28, 2023
- Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of PDUFA Regulatory Action Date - January 24, 2023
- FDA Rules Favorably On Efficacy Of Travivo (Gepirone ER) For Treatment Of Major Depressive Disorder - March 17, 2016
- Fabre-Kramer Looks Forward to FDA's Decision on Gepirone ER for the Treatment of Major Depressive Disorder - December 2, 2015
- Fabre Kramer Pharmaceuticals Receives Decision From FDA on GepironeER for Major Depressive Disorder - November 5, 2007
- Fabre-Kramer Refiles Gepirone ER with the FDA for the Treatment ofMajor Depressive Disorder - May 8, 2007
Exxua (gepirone) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.